webinar register page

Webinar banner
[FREE TALK] How to boost your compound value with Cross Indication Research?
The pharmaceutical industry is often seen as an expensive activity that requires considerable R&D investments with no guaranties of return. Success in these activities could be measured by the number of clinical trials (new or diversified indications) resulting from such investments as the more trials you can initiate the bigger the likelihood to deliver successful products. Some companies are better than others in converting the R&D budgets into Proof of Concept and new IP. Cross Indication Research is one of their secret weapon.

Based on real examples, learn how Cross Indication Research can support diversification of the indication space during drug discovery and development but also convert “old” compounds into new interesting therapeutic areas.

This approach is always based on in-depth understanding of the compound´s mode of action (MoA) together with hypotheses on the potential role of respective MoAs in the pathogenesis of different diseases. Proven activity of the compound´s MoA in respective disease models (including studies allowing human estimated dose predictions) can help boost your ROI by defining early clinical strategies, accelerating smart Proof of Concept while generating new IP.

Interested in learning how to maximize your R&D budget with Cross Indication Research?

In this 45-minute presentation, Dr. Ekkehard May, Head of Cross Indication Research, and Dr. Charlotte Kopitz, Head of Therapeutic Research, will cover:

• Indication diversification parallel value chain
• Life cycle Management of drugs
• Drug repurposing activities
• Biomarker-based identification of tumor patients
• Live Q&A session

[Can't join?] Don't worry, register anyway, the slides and recording will be sent to you after the webinar.
Webinar logo
* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



Dr. Charlotte Kopitz
Executive Vice-President & Head of Therapeutic Research @Nuvisan
Dr. Charlotte Kopitz is Biologist by training with a passion for applied research. She started academic research in the field of natural pest control/Zoology at the FU Berlin in 1997, followed by basic research on the autoimmune disease sprue, a PhD in the field of metastasis research at the Technical University Munich followed by a PostDoc in Experimental Oncology and Therapeutic Research at the Klinikum Rechts der Isar. In 2008 she took over the lead of an in vivo Laboratory in Oncology Research at Bayer including project leadership along the value chain, membership of the Global Bayer Animal Welfare Committee and Inclusion and the role as Inclusion & Diversity Advisor of the Bayer Pharma R&D organization. In 2019 she took over the responsibility for Pharmacology of the Innovation Campus Berlin at Bayer, preparing the transition to Nuvisan GmbH. At July 1st 2020 she became EVP and head of Therapeutic Research in the Innovation Campus Berlin as part of the Nuvisan family.
Dr. Ekkehard May
Head of Cross Indication Research @Nuvisan
With a solid scientific knowledge on a broad range of indications, pathomechanisms, and treatment paradigms acquired both in academia (US and EU) and pharmaceutical industry, Dr. Ekkehard May is a reputed senior scientist with a strong experience on early research up to phase II. For more than 15 years now, he has been leading or was integral part of pharma R&D projects. He lead teams over large parts of the pharmaceutical value chain from target identification to early clinical development, particularly with regard to indication exploration and drug positioning. Thus, Dr. May fostered a multitude of interfaces to BD&L, regulatory affairs, commercial, and marketing functions. Over the years, he continuously interacted and collaborated with external partners, CROs, clinics as well as academic KOLs. In July 2020, he joined Nuvisan as Head of Cross Indication Research at the Innovation Campus Berlin.